You are here

  • Home
  • Archive
  • Volume 70, Issue 5
  • Sleep problems are of higher priority for improvement for patients with ankylosing spondylitis than for patients with other inflammatory arthropathies

Article Text

Article menu
Download PDFPDF
Letters
Sleep problems are of higher priority for improvement for patients with ankylosing spondylitis than for patients with other inflammatory arthropathies
  1. Turid Heiberg1,2,
  2. Elisabeth Lie3,
  3. Désirée van der Heijde3,4,
  4. Tore K Kvien3
  1. 1Department for Research and Development, Oslo University Hospital, Ullevål, Oslo, Norway
  2. 2Lovisenberg Diakona College, Oslo, Norway
  3. 3Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
  4. 4Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
  1. Correspondence to Turid Heiberg PhD RN, Department for Research and Development, Oslo University Hospital, Ullevål, N-0407 Oslo, Norway; turid.heiberg{at}medisin.uio.no

https://doi.org/10.1136/ard.2010.133793

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The most widely used domains for the assessment of therapeutic efficacy in ankylosing spondylitis (AS) include patient global, pain, function, fatigue and inflammatory activity.1 A recently proposed composite score includes back pain, patient global, peripheral pain/swelling, duration of morning stiffness, fatigue and acute phase reactants.2 The selection of patient-reported outcomes in trials and clinical care should be consistent with outcomes that are important to patients,3 because health professionals and patients may have diverging opinions.4

    The aim of this post-hoc exploratory analysis was to examine priorities for improvement in dimensions of health across inflammatory rheumatic diseases, within the setting of the Norwegian disease-modifying antirheumatic drugs (NOR–DMARD) register.5 The study was approved by the regional ethical committee …

    View Full Text

    Footnotes

    • Funding NOR-DMARD has been supported by grants from the Norwegian government and from pharmaceutical companies (Abbott, BMS, MSD, Roche, Schering-Plough, UCB, Wyeth).

    • Patient consent Obtained.

    • Ethics approval The study was approved by the regional ethical committee.